Chromenone derivatives

Abstract

The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , n and R 9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

1 - 8 . (canceled) 
     
     
         9 . A compound of the formula XVI: 
       
         
           
           
               
               
           
         
       
       in which:
 R 1  is H or (1-4C)alkyl optionally substituted by 1, 2 or 3 substituents independently selected from halogen, hydroxy or (1-3C)alkoxy; 
 R 2  is (1-4C)alkyl or (1-4C)alkoxy, either of which can be optionally substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxy, (2-3C)alkenyl, (2-3C)alkynyl, (1-3C)alkoxy, cyano, (1-3C)alkylamino or di-[(1-3C)alkyl]amino; or 
 R 1  and R 2  together form a 3 to 8 membered nitrogen containing heterocyclyl ring system, which optionally contains 1 or 2 further heteroatoms selected from oxygen, nitrogen and sulphur, wherein a ring sulphur atom is optionally oxidised to form the S-oxide(s), said ring being optionally substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxy, (1-3C)alkyl, (2-3C)alkenyl, (2-3C)alkynyl, (1-3C)alkoxy, oxo, hydroxy-(1-3C)alkyl, halogeno-(1-3C)alkyl and (1-3C)alkoxy-(1-3C)alkyl; 
 n is 0, 1, 2, 3 or 4; and 
 each R 9  group is (1-3C)alkyl. 
 
     
     
         10 . A compound of the Formula XVI as aimed in claim  1  in which R 1  is methyl; R 2  is methyl; and n is 0.